- Journal Archives
- Volume 20
- Volume 19
- Volume 18
- Volume 17
- Volume 16
- Volume 15
- Volume 14
- Volume 13
- Volume 12
- Volume 11
- Volume 10
- Volume 9
- Volume 8
- Volume 7
- Volume 6
- Volume 5
- Volume 4
- Volume 3
- Volume 2
- Volume 1
- 2017-2018 Symposium
- 2016-2017 Symposium
- 2015-2016 Symposium
- 2014-2015 Symposium
- 2013-2014 Symposium
- 2012-2013 Symposium
- 2011-2012 Symposium
- 2010-2011 Symposium
- 2009-2010 Symposium
- 2008-2009 Symposium
- 2007-2008 Symposium
Currently viewing the tag: "Pfizer"
Scientists use brain scans to determine what makes long-term marriages last.
David Carradine’s widow files wrongful death suit against French production company.
MPAA considers whether to turn its litigious attentions to Ashton Kutcher for pirating a portion of his upcoming movie.
New patent [...]Continue Reading →
I respect the time, effort, and money that pharmaceutical companies devote to drug research and development, and advertising the drugs that are ultimately developed is an inevitable part of the research and development [...]Continue Reading →
In the news . . .
Sprint providing law enforcement with subscribers GPS information.
Is Wikipedia becoming an oligarchy?Continue Reading →
In the news . . .
Wired writer tries to find out if it’s possible to disappear in the digital world.
England’s proposed new copyright laws are extremely controversial.
Insurance company takes away Canadian woman’s long-term sick leave benefit after Facebook photos indicate she wasn’t suffering from depression.
Sony [...]Continue Reading →
Pfizer offered a major “mea culpa” last week when it agreed to pay $2.3 billion in fines for the “largest combined federal and state health care fraud settlement in the history of the Department of Justice.” The pharmaceutical company has ended up in this less than esteemed position as a result of its [...]Continue Reading →
On October 7, 2008 By JETLaw October 7, 2008
Pfizer, Inc., the world’s largest research-based pharmaceutical company, announced on October 1 that it plans to discontinue research and development in the areas of heart disease, cholesterol, obesity and bone health. The company predicated its decision on the scheduled 2011 expiration of the company’s patent for its bestselling, cholesterol-reducing drug, Lipitor. Research and [...]Continue Reading →
Recent Blog Posts
- Guest Post: Why Should Indian Sports Authorities Pay Heed to Aesthetic Sports?
- 2018 Symposium Announcement – Dramatic Changes: The Effect of International Trade on Intellectual Property and Human Rights
- Smart Contracts Are Useful, But Will Not Replace Dumb Contracts
- Hail Mary: Why Kaepernick Has No Prayer for Relief
- Ezekiel Elliott Suspension: It’s For Real This Time
- A Reevaluation of the Third-Party Doctrine
Tagsadvertising antitrust Apple books career celebrities contracts copyright copyright infringement courts creative content criminal law entertainment Facebook FCC film/television financial First Amendment games Google government intellectual property internet JETLaw journalism lawsuits legislation media medicine Monday Morning JETLawg music NFL patents privacy progress publicity rights radio social networking sports Supreme Court of the United States (SCOTUS) technology telecommunications trademarks Twitter U.S. Constitution